Open AccessAcute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report
Author(s) -
Hong-Beum Kim,
Sang-Gon Park,
Hong Ren,
SeongHo Kang,
Yong Sub Na
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i13.2833
Subject(s) - medicine , pembrolizumab , lung cancer , carboplatin , pathology , biopsy , chemoradiotherapy , cancer , acute myelomonocytic leukemia , fluorodeoxyglucose , chemotherapy , oncology , radiology , bone marrow , gastroenterology , positron emission tomography , immunotherapy , cisplatin
Pembrolizumab is a highly selective IgG4 kappa isotype monoclonal antibody against the programmed cell death-1 (PD-1) molecule. In the treatment of non-small cell lung cancer (NSCLC), pembrolizumab has demonstrated significant efficacy, significant survival outcomes, long-lasting responses, and a good safety profile compared with cytotoxic chemotherapy.